OTC: ZEOX · Life Sciences · 6 alerts · CIK 1557376
Share price
$0.7960Close, Nov 13
Market cap
$6.24M
Shares outstanding
7.84MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zeo ScientifiX, Inc. filings on SEC EDGAR ↗
Zeo ScientifiX announced that its manufacturing facility is the first to achieve Quality Management Systems (QMS) Certification under a newly established program by the Association for the Advancement of Blood & Biotherapies (AABB). This certification serves as an independent validation of the company's manufacturing quality and operational discipline in the regenerative medicine sector.
Counterparty
Association for the Advancement of Blood & Biotherapies
Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.
Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine and aesthetics. The transaction involves a share exchange that will result in Pluri owning 50% of ZEO, combining Pluri's 3D cell-expansion technology with ZEO's biologics manufacturing and physician sales network.
Zeo ScientifiX, Inc. reported a working capital deficit of $1,915,000 as of October 31, 2025, which improved to a positive $65,000 by June 30, 2026. The company remains dependent on external investment capital to fund operations and faces significant risks regarding supply chain stability and its ability to continue as a going concern.
Zeo ScientifiX, Inc. has changed its fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. The company will file a transition report on Form 10-KT for the eight-month period from November 1, 2025, through June 30, 2026.
Zeo ScientifiX announced plans to expand its commercial and provider-support operations into Georgia and Tennessee. The move follows the enactment of new state laws in both jurisdictions that establish frameworks for stem cell and regenerative medicine therapies. The expansion aims to support healthcare providers with biologics, education, and implementation support as they navigate these evolving state-level regulatory environments.